- Report
- May 2025
- 196 Pages
Global
From €3155EUR$3,545USD£2,731GBP
€3506EUR$3,939USD£3,034GBP
- Report
- February 2025
- 200 Pages
Global
From €3996EUR$4,490USD£3,459GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2482EUR$2,789USD£2,148GBP
- Report
- November 2022
- 154 Pages
Global
From €4450EUR$5,000USD£3,851GBP
- Drug Pipelines
- March 2022
- 900 Pages
Global
From €8010EUR$9,000USD£6,932GBP
- Report
- February 2022
- 360 Pages
United States
From €3204EUR$3,600USD£2,773GBP
- Report
- January 2023
- 189 Pages
Global
From €3738EUR$4,200USD£3,235GBP
- Report
- January 2024
- 200 Pages
Global
From €3694EUR$4,150USD£3,197GBP
- Report
- July 2024
- 150 Pages
Global
From €3338EUR$3,750USD£2,889GBP
- Report
- May 2024
- 298 Pages
Global
From €7076EUR$7,950USD£6,124GBP
- Report
- February 2022
- 185 Pages
Global
From €3204EUR$3,600USD£2,773GBP
- Report
- August 2022
- 417 Pages
Global
From €1780EUR$2,000USD£1,541GBP
Cemiplimab is a monoclonal antibody used in the treatment of certain types of cancer. It is used to treat advanced cutaneous squamous cell carcinoma (CSCC) and metastatic non-small cell lung cancer (NSCLC). Cemiplimab works by targeting a protein called PD-1, which is found on the surface of certain immune cells. By blocking PD-1, cemiplimab helps the immune system to recognize and attack cancer cells. Cemiplimab is administered intravenously and is usually given in combination with other cancer treatments.
Cemiplimab is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2018. It is currently the only approved PD-1 inhibitor for the treatment of CSCC and NSCLC.
Some companies in the cemiplimab market include Regeneron Pharmaceuticals, Sanofi, Merck, and Bristol-Myers Squibb. Show Less Read more
